Published • loading... • Updated
Roche’s Obesity Drug Boosts Blood Sugar Control, Drives 15.5% Weight Loss in Mid-Stage Trial
The highest dose brought 62% of patients into the non-diabetic range, and about 2% stopped treatment because of side effects.
- On Tuesday, Roche announced its experimental drug Enicepatide reduced blood sugar and body weight in type 2 diabetes patients during a mid-stage trial, with the once-weekly injection mimicking GLP-1 and GIP hormones.
- Roche acquired Enicepatide, formerly known as CT-388, from Carmot Therapeutics for $3.1 billion in 2023, targeting a weight-loss drug market expected to exceed $100 billion annually.
- Patients receiving the 24-milligram dose lost an average 15.5% of body weight after 48 weeks, with 62% achieving HbA1c levels below 5.7% and only 2% discontinuing due to side effects.
- Goldman Sachs analyst James Quigley said the data "look competitive" against rival drugs as Roche races to challenge market leaders Eli Lilly and Novo Nordisk.
- Late-Stage glycemic-control and cardiovascular studies are scheduled to begin in the first half of 2027, with analysts projecting a 2028 launch and $4 billion in peak sales.
Insights by Ground AI
Podcasts & Opinions
14 Articles
14 Articles
Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes
Roche is back with more data Tuesday for the lead drug it obtained from Carmot Therapeutics — this time from a mid-stage trial in overweight or obese people with type 2 diabetes. The Swiss drugmaker’s enicepatide ...
Coverage Details
Total News Sources14
Leaning Left1Leaning Right2Center4Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
14%
C 57%
R 29%
Factuality
To view factuality data please Upgrade to Premium
